Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0080375 |
| Name | gastroesophageal adenocarcinoma |
| Definition | A gastroesophageal cancer that has_material_basis_in abnormally proliferating cells, derives_from epithelial cells, which originate in glandular tissue. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Xrefs |
|
| Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer gastroesophageal cancer gastroesophageal adenocarcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| ARID1A inact mut | unspecified immune checkpoint inhibitor | gastroesophageal adenocarcinoma | not predictive | detail... |
| FGFR2 over exp | Bemarituzumab + Fluorouracil + Leucovorin + Oxaliplatin | gastroesophageal adenocarcinoma | predicted - sensitive | detail... |
| RAD51C R237* | Cisplatin + Fluorouracil + Trastuzumab | gastroesophageal adenocarcinoma | predicted - sensitive | detail... |
| ATM R1882* | Capecitabine + Oxaliplatin | gastroesophageal adenocarcinoma | predicted - sensitive | detail... |
| ATM W1058* ATM S1993fs | Fluorouracil + Leucovorin + Oxaliplatin | gastroesophageal adenocarcinoma | predicted - sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02578368 | Phase III | Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab | Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (FLOT5) | Completed | DEU | 0 |
| NCT02824042 | Phase I | Anetumab ravtansine + Itraconazole Anetumab ravtansine | Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | Completed | USA | NLD | FRA | ESP | BEL | AUS | 0 |
| NCT02954536 | Phase II | Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab | Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer | Completed | USA | 0 |
| NCT03337087 | Phase Ib/II | Fluorouracil + Leucovorin + Liposomal irinotecan + Rucaparib | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | Unknown status | USA | 0 |
| NCT03697304 | Phase II | Ezabenlimab Miptenalimab | Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours. | Completed | USA | GBR | CAN | 0 |
| NCT03783936 | Phase II | Avelumab + Trastuzumab Avelumab + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab | Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas | Completed | USA | 0 |
| NCT03821233 | Phase I | ZW49 | A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers | Completed | USA | CAN | AUS | 1 |
| NCT03921021 | Phase II | OBP-301 + Pembrolizumab | Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma | Completed | USA | 0 |
| NCT03929666 | Phase II | Cisplatin + Gemcitabine Cisplatin + Fluorouracil + Zanidatamab Capecitabine + Oxaliplatin + Zanidatamab Fluorouracil + Leucovorin + Oxaliplatin + Zanidatamab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Zanidatamab | A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | Completed | USA | CAN | 2 |
| NCT03986606 | Phase I | PSB205 | A Study of PSB205 in Subjects With Advanced Solid Tumors | Unknown status | USA | 0 |
| NCT04021108 | Phase II | Nivolumab Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin | Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) | Active, not recruiting | USA | 0 |
| NCT04029922 | Phase I | MT-5111 | Study of MT-5111 in HER2-positive Solid Tumors (MT-5111) | Terminated | USA | NZL | AUS | 0 |
| NCT04060342 | Phase Ib/II | GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | Terminated | USA | GBR | 0 |
| NCT04150640 | Phase II | Fluorouracil + Liposomal irinotecan + Oxaliplatin Fluorouracil + Liposomal irinotecan + Oxaliplatin + Trastuzumab | P2 5-FU, Oxaliplatin & Liposomal Irinotecan (Nal-IRI) in 1st Line Advanced Esophageal & Gastric | Recruiting | USA | 0 |
| NCT04164979 | Phase II | Cabozantinib + Pembrolizumab | Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma | Active, not recruiting | USA | 0 |
| NCT04166721 | Phase Ib/II | Atezolizumab + DKN-01 | WaKING: Wnt and checKpoint INhibition in Gastric Cancer | Active, not recruiting | GBR | 0 |
| NCT04198766 | Phase Ib/II | INBRX-106 INBRX-106 + Pembrolizumab Carboplatin + INBRX-106 + Nab-paclitaxel + Pembrolizumab Pembrolizumab Cisplatin + INBRX-106 + Pembrolizumab + Pemetrexed Disodium Carboplatin + INBRX-106 + Pembrolizumab + Pemetrexed Disodium | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | Active, not recruiting | USA | 3 |
| NCT04511039 | Phase I | Talazoparib + Trifluridine-tipiracil hydrochloride | Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer | Recruiting | USA | 0 |
| NCT04522336 | Phase I | Docetaxel + Fluorouracil + Pembrolizumab Fluorouracil + Oxaliplatin + Pembrolizumab | Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer | Active, not recruiting | USA | 0 |
| NCT04592653 | Phase Ib/II | ALKS 4230 ALKS 4230 + Pembrolizumab | Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) | Active, not recruiting | USA | ESP | 0 |
| NCT04602117 | Phase I | Paclitaxel + Trastuzumab Duocarmazine | Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | Withdrawn | USA | 0 |
| NCT04662710 | Phase III | Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin Capecitabine + Fluorouracil + Lenvatinib + Leucovorin + Oxaliplatin + Pembrolizumab | Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) (LEAP-015) | Completed | USA | TUR | POL | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CAN | BEL | AUS | ARG | 10 |
| NCT04798781 | Phase II | Pembrolizumab + Telatinib | Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma | Completed | USA | 0 |
| NCT04879368 | Phase III | Docetaxel Paclitaxel Trifluridine-tipiracil hydrochloride Nivolumab + Regorafenib Irinotecan | RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) | Completed | USA | ITA | ESP | DEU | AUT | AUS | 3 |
| NCT04984733 | Phase II | Nivolumab + Temozolomide | Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer (ELEVATE) | Completed | GBR | 0 |
| NCT05001347 | Phase II | Uliledlimab | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ) in Patients With Ovarian Cancer and Selected Solid Tumors | Completed | USA | 0 |
| NCT05027139 | Phase Ib/II | Evorpacept + Zanidatamab | A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer | Completed | USA | 0 |
| NCT05041153 | Phase I | Lenvatinib + Pembrolizumab | Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma | Recruiting | USA | 0 |
| NCT05070247 | Phase I | TAK-500 Pembrolizumab + TAK-500 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
| NCT05152147 | Phase III | Capecitabine + Oxaliplatin + Trastuzumab Capecitabine + Oxaliplatin + Zanidatamab Cisplatin + Fluorouracil + Trastuzumab Cisplatin + Fluorouracil + Zanidatamab Cisplatin + Fluorouracil + Tislelizumab + Zanidatamab Capecitabine + Oxaliplatin + Tislelizumab + Zanidatamab | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01) | Active, not recruiting | TUR | ROU | POL | NLD | ITA | IRL | GRC | GBR | FRA | EST | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 16 |
| NCT05153304 | Phase Ib/II | Ipilimumab + Nivolumab | A Phase I/II Study of Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers | Withdrawn | USA | 0 |
| NCT05427487 | Phase I | IVX037 IVX037 + Sintilimab | Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | Recruiting | AUS | 0 |
| NCT05523947 | Phase Ib/II | YH32367 | Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor | Recruiting | USA | AUS | 1 |
| NCT05620134 | Phase Ib/II | JK08 | A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Active, not recruiting | ESP | BEL | 0 |
| NCT05904496 | Phase I | BGB-30813 BGB-30813 + Tislelizumab | A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | Terminated | USA | ESP | AUS | 1 |
| NCT05977322 | Phase I | 177Lu-FF58 | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | Terminated | NLD | ISR | ESP | CHE | 0 |
| NCT05983432 | Phase I | BL-B01D1 | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | Recruiting | USA | ITA | FRA | ESP | 1 |
| NCT06043427 | Phase II | Paclitaxel + Ramucirumab Paclitaxel + Ramucirumab + Zanidatamab | Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma | Recruiting | CAN | 0 |
| NCT06123468 | Phase Ib/II | Sacituzumab govitecan-hziy | Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma | Completed | DEU | AUT | 0 |
| NCT06154291 | Phase Ib/II | XON7 | FIH XON7 in Advanced/Metastatic Solid Tumors (FIPO23) | Recruiting | FRA | BEL | 0 |
| NCT06203600 | Phase II | Paclitaxel + Ramucirumab Nivolumab + Paclitaxel + Ramucirumab | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | Recruiting | USA | 0 |
| NCT06469944 | Phase Ib/II | Capecitabine + Oxaliplatin + Pembrolizumab Fluorouracil + Leucovorin + Pembrolizumab + Sacituzumab tirumotecan Fluorouracil + Leucovorin + Patritumab deruxtecan + Pembrolizumab Capecitabine + Patritumab deruxtecan + Pembrolizumab Capecitabine + Pembrolizumab + Sacituzumab tirumotecan Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) | Recruiting | USA | NOR | ITA | FRA | DEU | CHE | BRA | 5 |
| NCT06529822 | Phase I | Personalized cancer vaccine + Poly ICLC | Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease | Recruiting | USA | 0 |
| NCT06623396 | Phase I | ATA2271 | A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer | Recruiting | USA | 0 |
| NCT06695845 | Phase II | Zanidatamab | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Recruiting | USA | ESP | 1 |
| NCT06731803 | Phase Ib/II | Fluorouracil + Leucovorin + Trastuzumab deruxtecan Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab deruxtecan | Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma (NeoART) | Active, not recruiting | DEU | AUT | 0 |
| NCT06789172 | Phase I | OKN4395 + Pembrolizumab OKN4395 Famotidine + OKN4395 | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors (INVOKE) | Recruiting | USA | GBR | AUS | 0 |
| NCT06923761 | Phase Ib/II | Cemiplimab + GRWD5769 GRWD5769 | EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1) (EMITT-1) | Recruiting | GBR | FRA | ESP | AUS | 0 |
| NCT06962137 | Phase II | Paclitaxel + Ramucirumab + Zolbetuximab | Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer (RAINSPOT) | Recruiting | BEL | 0 |
| NCT07176312 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Zanidatamab | Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients (ZANGEA) | Recruiting | DEU | 0 |
| NCT07488676 | Phase Ib/II | ASP546C | A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors | Recruiting | USA | 1 |
| NCT07554521 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Tislelizumab Cisplatin + Fluorouracil + Tislelizumab Capecitabine + Oxaliplatin + Tislelizumab | A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States | Recruiting | USA | 0 |